189 related articles for article (PubMed ID: 35016807)
21. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
22. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
23. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.
King R; Weilbaecher KN; McGill G; Cooley E; Mihm M; Fisher DE
Am J Pathol; 1999 Sep; 155(3):731-8. PubMed ID: 10487831
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of melanocytic neoplasms: application of a pan-melanoma antibody cocktail.
Orchard G
Br J Biomed Sci; 2002; 59(4):196-202. PubMed ID: 12572952
[TBL] [Abstract][Full Text] [Related]
25. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.
Rao Q; Wang Y; Xia QY; Shi SS; Shen Q; Tu P; Shi QL; Zhou XJ; Wu B
Int J Clin Exp Pathol; 2014; 7(3):1132-9. PubMed ID: 24696729
[TBL] [Abstract][Full Text] [Related]
26. Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: pseudomelanocytic nests or authentic melanocytic proliferation?
Silva CY; Goldberg LJ; Mahalingam M; Bhawan J; Wolpowitz D
J Cutan Pathol; 2011 Oct; 38(10):797-800. PubMed ID: 21812802
[TBL] [Abstract][Full Text] [Related]
27. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
28. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
30. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin.
Muzumdar S; Argraves M; Kristjansson A; Ferenczi K; Dadras SS
J Cutan Pathol; 2018 Apr; 45(4):263-268. PubMed ID: 29377259
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.
Kunc M; Żemierowska N; Skowronek F; Biernat W
Histopathology; 2023 Jul; 83(1):3-14. PubMed ID: 36942814
[TBL] [Abstract][Full Text] [Related]
32. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
33. Melanocytic differentiation is present in a significant proportion of nonpigmented diffuse neurofibromas: a potential diagnostic pitfall.
Pižem J; Nicholson KM; Mraz J; Prieto VG
Am J Surg Pathol; 2013 Aug; 37(8):1182-91. PubMed ID: 23715161
[TBL] [Abstract][Full Text] [Related]
34. HMB-45 immunohistochemical staining of conjunctival melanocytic lesions.
McDonnell JM; Sun YY; Wagner D
Ophthalmology; 1991 Apr; 98(4):453-8. PubMed ID: 1711186
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical distinction of epithelioid histiocytic proliferations from epithelioid melanocytic nevi.
Busam KJ; Granter SR; Iversen K; Jungbluth AA
Am J Dermatopathol; 2000 Jun; 22(3):237-41. PubMed ID: 10871066
[TBL] [Abstract][Full Text] [Related]
36. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics.
Koch MB; Shih IM; Weiss SW; Folpe AL
Am J Surg Pathol; 2001 Jan; 25(1):58-64. PubMed ID: 11145252
[TBL] [Abstract][Full Text] [Related]
37. Pathologist Characteristics Associated With Rendering Higher-Grade Diagnoses for Melanocytic Lesions.
Kerr KF; Elder DE; Piepkorn MW; Knezevich SR; Eguchi MM; Shucard HL; Reisch LM; Elmore JG; Barnhill RL
JAMA Dermatol; 2023 Dec; 159(12):1315-1322. PubMed ID: 37938821
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
Petersson S; Shubbar E; Enerbäck L; Enerbäck C
Melanoma Res; 2009 Aug; 19(4):215-25. PubMed ID: 19521263
[TBL] [Abstract][Full Text] [Related]
39. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of melanocytic antigen PNL2, Melan A, S100, and PGP 9.5 in equine melanocytic neoplasms.
Ramos-Vara JA; Frank CB; DuSold D; Miller MA
Vet Pathol; 2014 Jan; 51(1):161-6. PubMed ID: 23370093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
